<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834624</url>
  </required_header>
  <id_info>
    <org_study_id>1206415</org_study_id>
    <nct_id>NCT02834624</nct_id>
  </id_info>
  <brief_title>Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome</brief_title>
  <acronym>NEOSURF</acronym>
  <official_title>Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature infants frequently have trouble breathing after birth. If the respiratory disorder
      is caused by surfactant deficiency or dysfunction, the disease is treated with a medication
      called surfactant that is given to the infant through a tube inserted into the windpipe. This
      study will compare the safety of two of the commonly used surfactants, poractant and
      calfactant,in the United States. Poractant has added chemicals called phospholipids which are
      known to cause inflammation and irritation in the body of premature infants. The
      investigators will compare this to another similar surfactant that does not contain these
      chemicals by looking at samples from the windpipe, while the tube is in place, and from blood
      tests in the first few days of life.

      The investigators are hoping to learn whether calfactant is a safer therapeutic agent to
      treat respiratory distress syndrome in preterm infants compared to poractant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 infants were randomized to receive either poractant or calfactant for Respiratory Distress
      Syndrome.

      Tracheal aspirates were obtained to look for increase in macrophage and blood samples were
      drawn to look for markers of inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Blood C-reactive (CRP) Protein</measure>
    <time_frame>baseline, 48 hours</time_frame>
    <description>Difference between measurement of CRP at baseline and 48 hours after administration of surfactant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of Pulmonary Hemorrhage</measure>
    <time_frame>intraoperative</time_frame>
    <description>Significant and Persistent Blood present in the trachea during endotracheal tube suctioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Tracheal Macrophages</measure>
    <time_frame>baseline, 48 hours</time_frame>
    <description>measurement of lipid peroxidation in tracheal aspirate samples and cytology of tracheal aspirates.in tracheal aspirate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Calfactant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poractant Alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poractant alfa</intervention_name>
    <description>Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
    <arm_group_label>Poractant Alfa</arm_group_label>
    <other_name>Curosurf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calfactant</intervention_name>
    <description>Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist</description>
    <arm_group_label>Calfactant</arm_group_label>
    <other_name>Infasurf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled prior to delivery with signed informed consent and HIPAA by parents

          -  Gestational age of less than 35 weeks

          -  No maternal chorioamnionitis of other maternal or fetal infection

          -  Respiratory Distress Syndrome (RDS) determined by the attending neonatologist that
             needs to be treated with exogenous surfactant and mechanical ventilation

        Exclusion Criteria:

          -  Major Birth Defect, Malformation Syndrome

          -  Chromosomal or Inherited Metabolic Disorder

          -  Proven Presence of an Immunodeficiency

          -  Antenatal exposure of illicit substance (e.g., methamphetamines, cocaine, etc., but
             not marijuana)

          -  Birth Asphyxia (cord pH &lt;7.0, Apgar score of 3 or less at 10 minutes of age)

          -  HIV or other congenital viral, bacterial or fungal infection

          -  Lack of Parental consent of refusal of attending neonatologist to allow participation

          -  Discretion of the investigator

          -  The legal representative of the infant or the patient's primary physician are not
             committed to providing full, aggressive life support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Weeks</minimum_age>
    <maximum_age>35 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Lauriello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Missouri, Women's and Children's Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <results_first_submitted>November 2, 2016</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2017</results_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surfactant</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <keyword>inflammation</keyword>
  <keyword>c-reactive protein</keyword>
  <keyword>lipid peroxidation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
    <mesh_term>Poractant alfa</mesh_term>
    <mesh_term>Calfactant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Infants &lt; 35 weeks gestation requiring intubation and surfactant for Respiratory Distress Syndrome. Infants with suspected congenital infection, major birth defects, known chromosomal disorder, cord blood pH &lt; 7.0, or Apgar score of 3 or &lt; at 10 minutes were excluded. The infants were randomized to receive either Poractant or Calfactant.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Poractant</title>
          <description>Randomized to receive poractant alfa (Curosurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
        </group>
        <group group_id="P2">
          <title>Calfactant</title>
          <description>Randomized to receive calfactant (Infasurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Preterm infants less than 35 weeks gestation who required intubation for RDS and surfactant administration</population>
      <group_list>
        <group group_id="B1">
          <title>Poractant</title>
          <description>Randomized to receive poractant alfa (Curosurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
        </group>
        <group group_id="B2">
          <title>Calfactant</title>
          <description>Randomized to receive calfactant (Infasurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood C-reactive (CRP) Protein</title>
        <description>Difference between measurement of CRP at baseline and 48 hours after administration of surfactant</description>
        <time_frame>baseline, 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poractant</title>
            <description>Randomized to receive Poractant alfa (Curosurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
          </group>
          <group group_id="O2">
            <title>Calfactant</title>
            <description>Randomized to receive calfactant (Infasurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood C-reactive (CRP) Protein</title>
          <description>Difference between measurement of CRP at baseline and 48 hours after administration of surfactant</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.300" spread="1.644"/>
                    <measurement group_id="O2" value="0.193" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size calculations used a Chi-square for independence, u = 1, p =.05, power = .80, effect size = .60, which required 22 total subjects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Pulmonary Hemorrhage</title>
        <description>Significant and Persistent Blood present in the trachea during endotracheal tube suctioning.</description>
        <time_frame>intraoperative</time_frame>
        <population>This data is unavailable from the research department as it was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Poractant</title>
            <description>Randomized to receive poractant alfa (Curosurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
          </group>
          <group group_id="O2">
            <title>Calfactant</title>
            <description>Randomized to receive calfactant (Infasurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Pulmonary Hemorrhage</title>
          <description>Significant and Persistent Blood present in the trachea during endotracheal tube suctioning.</description>
          <population>This data is unavailable from the research department as it was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Tracheal Macrophages</title>
        <description>measurement of lipid peroxidation in tracheal aspirate samples and cytology of tracheal aspirates.in tracheal aspirate</description>
        <time_frame>baseline, 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Poractant</title>
            <description>Randomized to receive Poractant alfa (Curosurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
          </group>
          <group group_id="O2">
            <title>Calfactant</title>
            <description>Randomized to receive calfactant (Infasurf) as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Tracheal Macrophages</title>
          <description>measurement of lipid peroxidation in tracheal aspirate samples and cytology of tracheal aspirates.in tracheal aspirate</description>
          <units>white cells/high-powered field</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.8"/>
                    <measurement group_id="O2" value="2.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Calfactant</title>
          <description>Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
calfactant: Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist</description>
        </group>
        <group group_id="E2">
          <title>Poractant Alfa</title>
          <description>Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
Poractant alfa: Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Naomi Lauriello</name_or_title>
      <organization>University of Missouri-Columbia</organization>
      <phone>573-882-2272</phone>
      <email>lauriellon@health.missouri.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

